Method for generating influenza viruses and vaccines

• US 7,037,707 B2
• Filed: 09/04/2003
• Issued: 05/02/2006
• Est. Priority Date: 09/04/2003
• Status: Expired due to Fees

• Current Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories)
• Original Assignee: St Jude Children's Research Hospital Incorporated (Abbott Laboratories)
• Inventors: Ozaki, Hiroichi, Webster, Robert Gordon, Webby, Richard John
• Primary Examiner(s): Foley, Shanon
• Assistant Examiner(s): SALVOZA, M FRANCO G
• Application Number:
  US10/654,737
• Publication Number:
  US 20050054846A1
• Time in Patent Office: 971 Days
• Field of Search: 424/206.1, 424/199.1, 424/209.1, 435/235.1, 435/236, 435/320.1
• US Class Current: 435/235.1
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/4747 Apoptosis related proteins
• CPC Class Codes: C12N 2760/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain with the NS gene of the A/England/1/53 strain. The invention provides influenza viruses and vaccines generated in mammalian cells as well as methods for producing such. The invention further provides an influenza virus master strain and kits for generating reassortant influenza viruses in mammalian cell culture and methods of making and using the master strain.

Claims

1. A method for producing a reassortant influenza virus comprising transfecting host cells with expression plasmids containing PB2, PB1, PA, NP and M genes from A/PuertoRico/8/34 influenza strain, an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO;

6, and HA and NA genes from an influenza virus of interest other than A/England/1/53, to obtain a reassortant influenza virus.

2. The method of claim 1 wherein the NS gene has a sequence set forth in SEQ ID NO:

2.

3. The method of claim 1 wherein said host cells are mammalian cells.

4. The method of claim 3 wherein said mammalian cells are selected from the group consisting of cells suitable for preparing vaccines for use in humans.

5. The method of claim 4 wherein said mammalian cells are Vero cells.

6. The method of claim 1 wherein said influenza virus of interest is selected from the group consisting of human, avian, swine and equine.

7. A reassortant influenza virus strain comprising a modified A/PuertoRico/8/34 influenza strain, wherein an NS gene of the A/PuertoRico/8/34 influenza strain is replaced with an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO;

6, and HA and NA genes from an influenza virus strain of interest other than A/England/1/53.

8. A method of producing a reassortant influenza virus vaccine comprising transfecting cells with expression plasmids containing the PB2, PB1, PA, NP and M genes from an A/PuertoRico/8/34 influenza strain, an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO;

6, and HA and NA genes from an influenza virus of interest other than A/England/1/53, to obtain a reassortant influenza virus vaccine.

9. A reassortant influenza virus vaccine comprising a modified A/PuertoRico/8/34 influenza strain and a pharmaceutically acceptable carrier, wherein an NS gene of the A/PuertoRico/8/34 influenza strain is replaced with an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO;

6, and HA and NA genes from an influenza virus strain of interest other than A/England/1/53.

11. A kit for producing an influenza virus master strain comprising expression plasmids containing PB2, PB1, PA, NP and M genes from an A/PuertoRico/8/34 influenza strain and an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO;

6.

12. A modified A/PuertoRico/8/34 influenza virus master strain, wherein PB2, PB1, PA, NP and M genes are from A/PuertoRico/8/34 influenza strain, a NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO;

6, and HA and NA genes are from any influenza virus other than A/England/1/53.

13. A method of producing a reassortant influenza virus comprising infecting a host cell with the influenza virus master strain of claim 12 and an influenza virus of interest other than A/England/1/53, wherein the genes from the master strain and the virus of interest reassort in the host cell to produce a different virus strain.

14. An A/PuertoRico/8/34 master strain used for producing an influenza virus, the improvement which consists of replacing an NS gene of the A/PuertoRico/8/34 influenza strain with an NS gene encoding an NS1 protein having an amino acid sequence comprising SEO ID NO:

5 and an NS2 protein having an amino acid sequence comprising SEO ID NO;

6, and HA and NA genes from any influenza virus other than A/England/1/53.

15. A method for producing a reassortant influenza virus comprising transfecting host cells with expression plasmids containing PB2, PB1, PA, NP and M genes from A/PuertoRico/8/34 influenza strain, HA and NA genes from an influenza virus of interest other than A/England/1/53, and an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:

3 with one or more changes selected from the group consisting of amino acid substitutions at positions 21, 58, 60, 127, 174, and 189 and a deletion of amino acids 231–

238 and encoding an NS2 protein having an amino acid sequence comprising SEQ ID NO;

4 with one or more changes selected from the group consisting of amino acid substitutions at positions 16, 31, 86, and 107 to obtain a reassortant influenza virus.

10. The vaccine of claim 15, further comprising an adjuvant which enhances an influenza virus immune response.

16. The method of claim 15 wherein the substitution of the NS 1 amino acid sequence at position 21 is Gln to Arg, at position 58 is Thr to Ile, at position 60 is Val to Ala, at position 127 is Asn to Ser, at position 174 is Val to Ile, at position 189 is Asp to Asn, and the substitution of the NS2 amino acid sequence at position 16 is Met to Ile, at position 31 is Met to Ile, at position 86 is Lys to Arg, and at position 107 is Phe to Leu.